Psychiatry

Firefly Neuroscience’s White Paper Unveils BNA™ Platform’s Significant Impact on Disease Management in 2,253 U.S Patients

Retrieved on: 
Tuesday, March 5, 2024
BNA, Transcranial magnetic stimulation, My Little Pony, AI, FDA, WAVD, Psychiatry, GAD, Antidepressant, EEG, Patient, Attention deficit hyperactivity disorder, DSM-IV codes, ADHD, MDD, Depression

FAIRFAX, Va. and TORONTO, March 05, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly”), a pioneering AI company developing innovative neuroscientific solutions to improve outcomes for patients with mental illnesses and neurological disorders, today announced the findings presented in a 2023 white paper “Brain Network Analytics (BNA) in the Psychiatric Practice: Real-Life Data Analysis” by Charlotte Baumeister, Ph.D., with analysis by Offir Laufer, Ph.D. Firefly has entered into an agreement (as amended, the “Merger Agreement”) to merge with WaveDancer, Inc. (“WaveDancer”) (NASDAQ: WAVD), subject to the approval of the stockholders of Firefly and WaveDancer (the “Merger”).

Key Points: 
  • This FDA-approved 510(k) tool harnesses vast data sets, including thousands of normative, age-matched electroencephalogram (“EEG”) recordings, empowering clinicians to make informed decisions in therapy and disease management.
  • The results suggest the transformative potential of the BNA™ Platform to significantly improve psychiatric care.
  • With the potential to revolutionize disease management, enhance treatment outcomes, and improve the overall well-being of patients with mental illnesses and cognitive disorders, we believe the BNA™ Platform can have a transformative impact.
  • We believe these findings will pave the way for widespread adoption of the BNA™ Platform into standard patient management protocols.”

GH Research Reports Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
Thursday, February 29, 2024
PD, Research, New Drug Application, TRD, GHRS, FDA, BDII, Food, EPO, Rat, Psychiatry, Patent, PPD, Patient, IDR, DSM-IV codes, Clinical trial, Insurance, Psychotherapy, G&A, MDD, IND, European Patent Convention, Pharmaceutical industry

DUBLIN, Ireland, Feb. 29, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the year ended December 31, 2023, and provided updates on its business.

Key Points: 
  • DUBLIN, Ireland, Feb. 29, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the year ended December 31, 2023, and provided updates on its business.
  • As announced in November 2023, both trials were recruiting slower than anticipated, in part due to the closure, for business reasons, of one of the two sites activated in each trial.
  • Subsequently, we have implemented measures to strengthen recruitment of both trials, including the addition of further clinical trial sites.
  • For the trial in patients with PPD (GH001-PPD-203), we now expect completion and availability of top-line data in the third quarter of 2024.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LifeStance Health Group, Inc. - LFST

Retrieved on: 
Wednesday, February 28, 2024
Pomerantz, Life, Hindenburg, IPO, Patient, LLP, Hindenburg Research, Psychiatry, Environment

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (NASDAQ: LFST).

Key Points: 
  • NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (NASDAQ: LFST).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether LifeStance and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Study Surmounts Barrier to Measuring Healthcare Worker Exposure to Workplace Violence

Retrieved on: 
Tuesday, February 27, 2024
School, Incidence, Anxiety, Hospital, Violence, Doctor of Philosophy, Military, Health, MD, Emergency medicine, Research, Workplace violence, Quality, Foot, FAAN, WPV, Aggression, Outline of health sciences, Safety, Joint Commission, APRN, Patient safety, Emergency, Organization, Journal, Yale University, Psychiatry, FACEP, Editorial, Depression, Nursing

OAKBROOK TERRACE, Illinois, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Workplace violence (WPV), including physical assaults and verbal threats, is a pervasive and significant issue for healthcare workers and organizations.

Key Points: 
  • OAKBROOK TERRACE, Illinois, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Workplace violence (WPV), including physical assaults and verbal threats, is a pervasive and significant issue for healthcare workers and organizations.
  • WPV directly harms healthcare workers and increases their anxiety, depression and staff turnover.
  • Rates of WPV are likely underestimated because past studies have mostly used surveys that rely on recall of past events.
  • A study featured in the March 2024 issue of The Joint Commission Journal on Quality and Patient Safety (JQPS) overcomes this important barrier by precisely measuring nurse and patient care assistant exposure rates to patient aggression in real time, shedding light on prevention and management measures.

Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Retrieved on: 
Friday, February 23, 2024
Therapy, Reward, Alcoholism, Ministry, NET, Serotonin, Dopamine, Norepinephrine, Safety, MEAI, CWY, Patient, Clinical trial, Yale school, DAT, Psychiatry, Sheba Medical Center, Research, Pharmaceutical industry

Vancouver, Canada, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce it has received approval from the Ministry of Health of Israel to commence its phase I/IIa clinical trial for alcohol use disorder (AUD) patients using the company's proprietary MEAI-based (5-methoxy-2-aminoindane) CMND-100 oral capsule.

Key Points: 
  • "We are thrilled to receive approval to commence our phase I/IIa clinical trial for our lead drug candidate, CMND-100, which has been shown to be safe and effective in preclinical studies.
  • This is the most important milestone for the company to date and marks our transition to a clinical- stage pharmaceutical company.
  • The Clearmind team has been working tirelessly on the research and development of a novel treatment to the global epidemic of alcoholism.
  • We are eager to continue our work with patients in need of help,” said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LifeStance Health Group, Inc. - LFST

Retrieved on: 
Tuesday, February 20, 2024
Pomerantz, Life, Prior, Hindenburg, IPO, Patient, LLP, Hindenburg Research, Psychiatry, Environment

NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (NASDAQ: LFST).

Key Points: 
  • NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (NASDAQ: LFST).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether LifeStance and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, February 20, 2024
Shift, Acquisition, DSM-IV codes, Fibromyalgia, Central nervous system, Total, New Drug Application, MD, Narcolepsy, FDA, Marketing, Smoking, Food, Somnolence, Growth, SYMPHONY, Reboxetine, Psychiatry, Dextromethorphan/bupropion, Migraine, FOCUS, Safety, Therapy, Medicare, NMDA, CNS, Food and Drug Administration, BED, Webcast, Depression, Binge eating disorder, Patient, Agitation, Shirin David, Medicaid, SWD, Breakthrough therapy, MDD, NDA, Prescription, Pharmaceutical industry

Auvelity® net product sales were $49.0 million and $130.1 million for the fourth quarter and full year of 2023, the first full year of launch.

Key Points: 
  • Auvelity® net product sales were $49.0 million and $130.1 million for the fourth quarter and full year of 2023, the first full year of launch.
  • Total costs of revenue were $7.4 million and $26.1 million for the fourth quarter and full year of 2023, respectively.
  • Approximately 84,000 prescriptions were written for Auvelity in the fourth quarter of 2023, representing a 23% sequential increase versus the third quarter of 2023.
  • Axsome will host a conference call and webcast today at 8:00 AM Eastern to discuss fourth quarter and full year 2023 financial results as well as to provide a corporate update.

Scilex Holding Company Announces Publication in Anesthesiology Journal of Results from an Investigator-Initiated Research Study Using ZTlido® for the Treatment of Chronic Neck Pain¹

Retrieved on: 
Tuesday, February 20, 2024
PALO, Prevalence, Neck pain, Lidocaine, Physical medicine and rehabilitation, Neurology, Anesthesiology, American Medical Association, JAMA, Outline of health sciences, Disability, Chronic pain, Behavioural sciences, COVID, Patient, Journal, Neck, Psychiatry, Clutch (eggs), Rehabilitation, Pharmaceutical industry

PALO ALTO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced publication in Anesthesiology Journal of results from an investigator-initiated research study using ZTlido® for the treatment of chronic neck pain.

Key Points: 
  • PALO ALTO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced publication in Anesthesiology Journal of results from an investigator-initiated research study using ZTlido® for the treatment of chronic neck pain.
  • The primary outcome measure was mean reduction in average neck pain coupled with the Patient Global Impression of Change.
  • Neck pain, or cervicalgia, is one of the most common pain presentations in U.S. and the 4th leading cause of disability.
  • According to a 2020 JAMA publication (Journal of the American Medical Association), the U.S. low back and neck pain market is estimated at $134.5B.4

Asha Therapeutics to Present at AD/PD™ 2024 International Conference and Announces Clinical Development Plan for Lead Programs Anticipated to Enter Clinical Trials this Year and Welcomes Two New SAB Members

Retrieved on: 
Friday, March 8, 2024
Technology, Biotechnology, Health, Other Health, Pharmaceutical, Oncology, Other Science, Other Technology, Research, Software, General Health, Science, Data Management, Clinical Trials, Community health, GSK, AbbVie, Huntington's disease, University, Mathematics, Emory University, Behavioral neurology, Pathology, School, Alzheimer's disease, Johnson & Johnson, Drug design, Gold, Bristol Myers Squibb, Johns Hopkins, Disorder, Psychiatry, Derek, UCB, Computer science, American Neurological Association, Asha, Parkinson's Foundation, Conference, Chemistry, Safety, Amelioration, CNS, Behavioural sciences, Medical school, MD, Neurology, Patient, Florida College, Disease, Publication, DRS, Pharmaceutical industry

Dr. Heckmann’s presentation is titled ASHA-091: Novel Pharmacological Targeting of Mitochondrial Dysfunction to Ameliorate Parkinson’s & Alzheimer’s Disease Pathology.

Key Points: 
  • Dr. Heckmann’s presentation is titled ASHA-091: Novel Pharmacological Targeting of Mitochondrial Dysfunction to Ameliorate Parkinson’s & Alzheimer’s Disease Pathology.
  • ASHA-091 restores normal mitochondrial function and has demonstrated disease modifying efficacy as a functional cure in preclinical disease models.
  • In preparation for clinical transition, Asha has appointed Dr. Michael Gold and Dr. Allan Levey to their Scientific Advisory Board.
  • Their expertise comes at a pivotal moment for Asha as we transition our first-in-class lead programs designed using our PRISM™ technology to clinical trials.

MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder

Retrieved on: 
Thursday, March 7, 2024
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Anxiety, Week, Doctor of Philosophy, MD, MindMed, FDA, GAD, University, Patient, Psychiatry, Medicine, Pharmaceutical industry

The Company also announced that its Phase 2b study of MM120 in GAD met its key secondary endpoint, and 12-week topline data demonstrated clinically and statistically significant durability of activity observed through Week 12.

Key Points: 
  • The Company also announced that its Phase 2b study of MM120 in GAD met its key secondary endpoint, and 12-week topline data demonstrated clinically and statistically significant durability of activity observed through Week 12.
  • MM120 was administered as a single dose in a monitored clinical setting with no additional therapeutic intervention.
  • “I’ve conducted clinical research studies in psychiatry for over two decades and have seen studies of many drugs under development for the treatment of anxiety.
  • MindMed management will host a webcast at 8:00 am ET today to discuss the Phase 2b results of MM120 in GAD.